The PVT1, HULC, and HOTTIP expression changes due to treatment in Diffuse Large B-cell lymphoma

Author:

Shahsavari MiladORCID,Arbabian Sedigheh,Hosseini Farzaneh,Razavi Mohamad RezaORCID

Abstract

AbstractDiffuse large B-cell lymphoma is the most common histological subtype of non-Hodgkin’s lymphomas. It is an aggressive malignancy that displays great heterogeneity in morphology, genetics, biological behavior and treatment response owing to chromatin remodeling and epigenetics.Bioinformatic-based approaches were used to understand the possible signaling pathways of the three lncRNAsPVT1,HULC, andHOTTIP. Furthermore, their expression levels were quantitatively evaluated in 100 patients before and after the treatment.The results revealed that gene expression was significantly upregulated inPVT1,HULC, andHOTTIPby 7.39±8.48-, 5.924±7.536-, and 4.137±5.863 fold, respectively, relative to normal cases. Post-treatment measurement of lncRNA expression indicated thatPVT1andHOTTIPwere significantly downregulated.Interestingly, the expression levels ofPVT1,HULC, andHOTTIPwere significantly higher in DLBCL patients aged > 60 years than in those aged < 60 years. In addition, there was a significant positive correlation betweenHULCandHOTTIPexpression.The analysis of overexpressed lncRNA-miRNA interaction indicated different deregulated miRNA targets and the protein targets of upregulated lncRNAs are mainly with histone modification, DNA methylation/demethylation, and protein methyltransferase activity.Summary blurbThe lncRNAsPVT1,HULC, andHOTTIPexpression is significantly upregulated before treatment and reduce to normal level after treatment. It can be used as diagnostic marker or prognostic means especially in Relapsed/refractory DLBCL.

Publisher

Cold Spring Harbor Laboratory

Reference43 articles.

1. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

2. Diffuse large B-cell lymphoma: R-CHOP failure-what to do?;Hematology Am Soc Hematol Educ Program,2016

3. Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma-Results from MC078E;Blood,2020

4. Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment;Oncologist,2022

5. Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma;Cancer J,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3